WeightWatchers (NASDAQ: WW) ("WeightWatchers," "WW," or the "Company"), the global leader in science-backed weight management, today announced a pharmacy ...

Disparities in prescribing semaglutide and tirzepatide for obesity reveal social factors affecting access and highlight the ...

Semaglutide and tirzepatide prescriptions within Epic-affiliated health care systems increased slightly between 2021 and 2024, but ...

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

Mounjaro, initially for type 2 diabetes, gains popularity for weight loss, yet users report severe side effects. Ellie Marie, ...

New Integration with Gifthealth Simplifies Fulfillment and Medication Visibility for WeightWatchers Clinic MembersNEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WeightWatchers (NASDAQ: WW) ...

On Friday, Mad Money host Jim Cramer took a close look at what he called one of the most important stretches of the earnings ...

Hims & Hers Health (HIMS) stock surges following a partnership with Novo Nordisk (NVO) to sell the Danish drugmaker's weight ...

Mounjaro (tirzepatide) is quickly becoming a breakthrough option for people managing type 2 diabetes and those seeking ...

A judge denied compounders' request to keep making off-brand Wegovy and Ozempic after the FDA removed semaglutide from its shortage list.

Medicare coverage of obesity medications could drive a substantial rise in healthcare spending, according to a new study. A microsimulation model published in JAMA Health Forum projected that Medicare ...

Eli Lilly and Company's orforglipron had good results in Type 2 diabetes trials, potentially becoming the first scalable oral ...